{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:03:49Z","timestamp":1747181029523,"version":"3.40.5"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>In the Dutch Childhood Oncology Group ALL11 protocol, PEGasparaginase dosing was individualized for standard-risk and medium-risk patients with acute lymphoblastic leukemia. After using our pragmatic old guideline, we aimed to improve individualized PEGasparaginase dosing by developing a population pharmacokinetic model\u2013based dosing guideline.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method:<\/jats:title>\n            <jats:p>After the 3 doses of 1500 IU\/m<jats:sup>2<\/jats:sup> administered in induction, standard-risk patients received 1 individualized dose and medium-risk patients 14, targeting trough activity levels between 100 and 250 IU\/L. The effectiveness, adherence, and toxicity of our new dosing guideline was assessed and compared with the old guideline.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In total, 92 patients (714 samples) were included in the new dosing group and 509 patients (4539 samples) were included in the old dosing group. Comparing the effectiveness, we found that 32% (22\/67) of patients in the new and 13% (47\/354) of patients in the old dosing group were within the target range after the first individualized dose (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). Among medium-risk patients, a median of 3 dose reductions was needed to reach and maintain levels within the target range in the new dosing group compared with 5 in the old dosing group (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). With a continuous PEGasparaginase dosing schedule, target trough activity levels were reached after 2 dose reductions in the new group versus 4 in the old dosing group. The adherence to the new guideline was &gt;99%, with 6\/714 recommended doses deviating from the guideline. With exception of a lower proportion of patients with increased (\u2265grade 3) serum alanine transaminase (34% new vs 64% old, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05) in the new dosing group, toxicity was comparable between guidelines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>With the new dosing guideline, fewer dose-reduction steps are necessary to reach and remain within the target. The high adherence rate emphasized its simplicity and practicality, confirming that it can be easily integrated into clinical practice.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001252","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T22:11:11Z","timestamp":1723587071000},"page":"289-296","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A Refined Population Pharmacokinetic Model\u2013Based Guideline for Individualized PEGasparaginase Dosing in Pediatric Acute Lymphoblastic Leukemia"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2816-2610","authenticated-orcid":false,"given":"Leiah J.","family":"Brigitha","sequence":"first","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, the Netherlands; and"},{"name":"Pediatric Oncology and Hematology, Erasmus MC\u2013Sophia Children's Hospital, Rotterdam, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Zaky","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, the Netherlands; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Pieters","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, the Netherlands; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge M.","family":"van der Sluis","sequence":"additional","affiliation":[{"name":"Princess M\u00e1xima Center for Pediatric Oncology, Utrecht, the Netherlands; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"key":"R1-20250314","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/bjh.16254","article-title":"Acute lymphoblastic leukaemia patients treated with PEGasparaginase develop antibodies to PEG and the succinate linker","volume":"189","author":"Kloos","year":"2020","journal-title":"Br J Haematol"},{"key":"R2-20250314","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ejca.2021.08.025","article-title":"How much asparaginase is needed for optimal outcome in childhood acute lymphoblastic leukaemia? A systematic review","volume":"157","author":"Brigitha","year":"2021","journal-title":"Eur J Cancer"},{"key":"R3-20250314","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1200\/JCO.19.02292","article-title":"Individualized asparaginase dosing in childhood acute lymphoblastic leukemia","volume":"38","author":"Kloos","year":"2020","journal-title":"J Clin Oncol"},{"key":"R4-20250314","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1200\/JCO.19.03024","article-title":"Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol"},{"key":"R5-20250314","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood.2020006583","article-title":"Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia","volume":"137","author":"Gottschalk Hojfeldt","year":"2021","journal-title":"Blood"},{"key":"R6-20250314","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/0959-8049(96)00131-1","article-title":"Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations","volume":"32A","author":"Boos","year":"1996","journal-title":"Eur J Cancer"},{"key":"R8-20250314","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1046\/j.0306-5251.2001.01464.x","article-title":"Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries","volume":"52","author":"Albertsen","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"R9-20250314","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/sj.leu.2403143","article-title":"Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL","volume":"17","author":"Appel","year":"2003","journal-title":"Leukemia"},{"key":"R10-20250314","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1046\/j.1365-2141.1997.d01-2089.x","article-title":"Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia","volume":"96","author":"Ahlke","year":"1997","journal-title":"Br J Haematol"},{"key":"R11-20250314","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","article-title":"A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study","volume":"99","author":"Avramis","year":"2002","journal-title":"Blood"},{"key":"R12-20250314","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3324\/haematol.2015.137380","article-title":"Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation","volume":"101","author":"van der Sluis","year":"2016","journal-title":"Haematologica"},{"key":"R13-20250314","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1016\/S1470-2045(16)30035-3","article-title":"Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus","volume":"17","author":"Schmiegelow","year":"2016","journal-title":"Lancet Oncol"},{"key":"R14-20250314","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2013-10-534347","article-title":"A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia","volume":"123","author":"Tong","year":"2014","journal-title":"Blood"},{"key":"R15-20250314","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2019.242289","article-title":"Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model","volume":"106","author":"Kloos","year":"2021","journal-title":"Haematologica"},{"key":"R16-20250314","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1200\/JCO.22.02705","article-title":"Improved outcome for ALL by prolonging therapy for IKZF1 deletion and decreasing therapy for other risk groups","volume":"41","author":"Pieters","year":"2023","journal-title":"J Clin Oncol"},{"key":"R17-20250314","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1200\/JCO.23.01797","article-title":"Continuous PEGasparaginase dosing reduces hypersensitivity reactions in pediatric ALL: a Dutch childhood oncology group ALL11 randomized trial","volume":"42","author":"van der Sluis","year":"2024","journal-title":"J Clin Oncol"},{"key":"R19-20250314","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.3324\/haematol.2014.109413","article-title":"Toxicity of very prolonged PEGasparaginase and Erwiniaasparaginase courses in relation to asparaginase activity levels with a special focus on dyslipidemia","volume":"99","author":"Tong","year":"2014","journal-title":"Haematologica"},{"key":"R20-20250314","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/bloodadvances.2021005631","article-title":"Asparaginase enzyme activity levels and toxicity in childhood acute lymphoblastic leukemia: a NOPHO ALL2008 study","volume":"6","author":"Lynggaard","year":"2022","journal-title":"Blood Adv"},{"key":"R21-20250314","doi-asserted-by":"crossref","first-page":"e26651","DOI":"10.1002\/pbc.26651","article-title":"A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia","volume":"64","author":"Kloos","year":"2017","journal-title":"Pediatr Blood Cancer"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T15:03:14Z","timestamp":1741964594000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001252","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"type":"print","value":"0163-4356"},{"type":"electronic","value":"1536-3694"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"assertion":[{"value":"2024-04-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}